Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight

3. Merus N.V. (NASDAQ:MRUS)

Number of Hedge Fund Holders: 48

Calling Merus N.V. (NASDAQ:MRUS) a speculative stock, Cramer said:

“Okay, now this is a stock… you and I both know… This is one of those things that, it may not work out. They do have some good news. They have FDA approval of a drug, but it is still very, very speculative”

Merus (NASDAQ:MRUS) is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, with several candidates in clinical trials for the treatment of various cancers. Recently, it received approval from the U.S. Food and Drug Administration (FDA) for its therapy, Bizengri, which targets the NRG1 gene. This gene is linked to the formation and progression of multiple types of tumors, including those associated with lung and pancreatic cancers.

Bizengri marks the company’s first commercial product, providing a treatment option for patients with these aggressive cancers who have experienced disease progression despite prior systemic therapies. The FDA’s approval of Bizengri offers hope to individuals facing these hard-to-treat cancers, and it is expected to be available to patients in the near future.

Additionally, recently, it was announced that Merus (NASDAQ:MRUS) and Partner Therapeutics, Inc. have entered into an exclusive agreement granting PTx the rights to commercialize zenocutuzumab (Zeno) for treating NRG1 fusion-positive cancer in the U.S. Merus will receive an upfront payment, milestone payments, and royalties based on future sales of Zeno in the U.S. following a transition period.